Olanzapine
Bipolar Disorder
Floatz Rating
BBB72/100
Confidence
Indicative
Sponsor
Boryung Pharmaceutical Co., Ltd
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
71High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07263191CT.gov A Study of Olanzapine in Participants With Bipolar Disorder. | — | Recruiting | — | — | — |
NCT02893371CT.gov Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies | — | Terminated | — | — | — |
NCT02562287CT.gov Clozapine Versus Other Atypical Antipsychotics for Bipolar Disorder | — | Unknown | — | — | — |
NCT02287259CT.gov Olanzapine Versus Lithium in the Treatment of Acute Depression in Patients With Bipolar II or Bipolar Not Otherwise Specified(OL Study) | — | Completed | — | — | — |
NCT02087579CT.gov Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants | — | Completed | — | — | — |
NCT01893229CT.gov Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania | — | Unknown | — | — | — |
NCT01498770CT.gov An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308) | — | Completed | — | — | — |
NCT02582736CT.gov Antipsychotics and Risk of Hyperglycemic Emergencies | — | Completed | — | — | — |
NCT01303601CT.gov Efficacy of Olanzapine Monotherapy for Treatment Bipolar Ⅰ Depression | — | Completed | — | — | — |
NCT01864551CT.gov Olanzapine Compared to Lamotrigine in the Prevention of Depressive Episode in the Patients With Bipolar Disorder | — | Completed | — | — | — |
Show 32 more trialsShow fewer
NCT01000402CT.gov Juvenile Bipolar Disorder Outpatient Program | — | Unknown | — | — | — |
NCT00520507CT.gov An Investigation of the Sleep Architecture and Consequent Cognitive Changes in Olanzapine-Treated Depressed Patients | — | Completed | — | — | — |
NCT00512070CT.gov Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine | — | Completed | — | — | — |
NCT00510211CT.gov An Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients. | — | Completed | — | — | — |
NCT00391222CT.gov A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder | — | Completed | — | — | — |
NCT00490971CT.gov A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder | — | Completed | — | — | — |
NCT00205699CT.gov Metabolic Effects of Antipsychotics in Children | — | Completed | — | — | — |
NCT00303602CT.gov Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height) | — | Completed | — | — | — |
NCT00259272CT.gov Validation of Multidimensional Assessment of THYmic States (MATHYS): A Study in a Population of Bipolar Patients Treated With Olanzapine | — | Completed | — | — | — |
NCT00159783CT.gov 40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857) | — | Completed | — | — | — |
NCT00186017CT.gov Short Term Rescue Study of Olanzapine | — | Completed | — | — | — |
NCT00129220CT.gov Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder | — | Completed | — | — | — |
NCT00113594CT.gov Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder | — | Completed | — | — | — |
NCT00143182CT.gov 9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED) | — | Completed | — | — | — |
NCT00159796CT.gov 3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009) | — | Completed | — | — | — |
NCT00159744CT.gov 3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008) | — | Completed | — | — | — |
NCT00191997CT.gov Optimal Length of Treatment Continuation With Olanzapine After Remission of Manic or Mixed Episode | — | Completed | — | — | — |
NCT00094549CT.gov Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder | — | Completed | — | — | — |
NCT00767715CT.gov A Study in the Treatment of Acute Mania | — | Terminated | — | — | — |
NCT00190892CT.gov Olanzapine Plus Carbamazepine in the Treatment of Bipolar I Mania | — | Completed | — | — | — |
NCT00485680CT.gov Olanzapine Versus Comparator in the Treatment of Bipolar Disorder | — | Completed | — | — | — |
NCT00485771CT.gov Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression | — | Completed | — | — | — |
NCT00071253CT.gov Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness | — | Terminated | — | — | — |
NCT00050206CT.gov Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder | — | Completed | — | — | — |
NCT00048802CT.gov Treatment and Outcome of Early Onset Bipolar Disorder | — | Completed | — | — | — |
NCT00194064CT.gov Pilot Study Evaluating the Safety and Efficacy of Open-Label Olanzapine | — | Terminated | — | — | — |
NCT00202293CT.gov Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features | — | Completed | — | — | — |
NCT00034580CT.gov Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder | — | Completed | — | — | — |
NCT00177567CT.gov Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study | — | Completed | — | — | — |
NCT00182013CT.gov Open-Label Comparative Study of Risperidone Versus Olanzapine Versus Quetiapine for Mania in Children and Adolescents With Bipolar I and Bipolar II Disorder | — | Completed | — | — | — |
NCT00181935CT.gov Risperidone Versus Olanzapine for Mania in Preschool Children 4 to 6 Years of Age With Bipolar Disorder | — | Completed | — | — | — |
NCT00183612CT.gov Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bipolar Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Olanzapine (this asset) | Boryung Pharmaceutical Co., Ltd | Approved | BBB · 72 |
| Asenapine | Dr. Stavroula Rakitzi | P4 | BBB |
| Lithium, Elemental | University of Aarhus | P4 | BBB |
| Lamotrigine | Johns Hopkins University | P4 | BBB |
| Quetiapine | First Affiliated Hospital of Zhejiang University | P4 | BBB |
| Escitalopram | First Affiliated Hospital of Zhejiang University | P4 | BBB |
| Citalopram | University of Texas Southwestern Medical Center | P4 | BBB |
| Paroxetine | Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital | P4 | BBB |
| Valproic Acid | University of New Mexico | P4 | BBB |
+42 more in the Bipolar Disorder cohort
Other indications for Olanzapine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Schizophreniform Disorder | — | P4 | A · 83 |
| Schizoaffective Disorder | — | P4 | BBB · 77 |
| Psychotic Disorder | — | P4 | BBB · 77 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Olanzapine in Bipolar Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/olanzapine-bipolar-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →